Relationship Between Adherence to Interferons to Treat Multiple Sclerosis and the Number and Severity of RelapsesThis study examined pharmacy and medical claims data between 2006-2008 of multiple sclerosis (MS) patients on an interferon beta product (Rebif®, Avonex®, or Betaseron®) to determine their adherence with these treatments, the optimal adherence rate to maximize clinical outcomes, and the impact of adherence on the number and severity of relapses. Adherence was measured using the Medication Possession Ratio (MPR), which represents the percentage of days patients have medication available to take. The study found that the average MPR varied between 72% and 76%, and the threshold analysis determined that the optimal adherence rate is approximately 85%. Study results showed that patients who received interferon through a specialty pharmacy were more adherent than those using a retail pharmacy. Patients who were classified as adherent through 2007 had a significantly lower risk of relapse in 2008, and patients who were adherent also had a significantly lower risk of severe relapse than those who were nonadherent. The results of this study are important in determining an optimal cutoff point for adherence, and in establishing the link between adherence and adverse clinical outcomes. Presented October 26, 2009, at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 12th Annual European Congress. More information about this study can be found in the attached abstract and clinical brief. R.J. Faris,1 S. Steinberg, 1, 2 C.F. Chang, 2 J. Tang J, 1 M Tankersley1 1Accredo Health Group, Memphis, TN, USA, All rights in the product names of all third-party products listed in this release, whether or not appearing with the trademark symbol, belong exclusively to their respective owners. |